Project Grant R01AI183877
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $360,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Virginia Polytechnic Institute & State University (Virginia Tech) to develop a gerbil model to delineate the mechanism of Hepatitis E Virus (HEV) extrahepatic pathogenesis. The key objectives are to: 1) Determine the effect of HEV-3-induced pyroptosis in neurovascular unit (NVU) cells and identify the mechanisms of...
- This federal Project Grant award of $440,000.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to create a transgenic pig model that is permissive to Hepatitis B Virus (HBV) infection. The primary goals are to evaluate the efficiency of HBV infection and replication in pigs in vitro and in vivo, and to develop a transgenic pig model expressing the human sodium taurocholate cotransporting...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $972,583 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to the Research Institute at Nationwide Children's Hospital. The grant, awarded on March 21, 2025, supports research to define the protective CD4+ T cell signature that enables effective CD8+ T cell immunity against the Hepatitis C Virus (HCV). The goal is to advance the development of a vaccine to prevent chronic HCV...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $356,389 to Emory University to investigate the role of intrahepatic (liver-resident) plasma cells in clearing hepatitis C virus (HCV) infection. The objective is to determine the mechanistic origins of these liver-resident plasma cells and identify prerequisites for designing effective HCV...
- This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) provides $1,376,398.00 to Yale University to develop a "fully humanized mouse liver" model to study the key features of alcohol-associated hepatitis (AAH). The project aims to utilize this novel in vivo model, which incorporates human hepatocytes and non-parenchymal cells, to investigate the role of human non-parenchymal cells in driving...
- This Project Grant award of $272,133 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop a low-cost, rapid antigen test for diagnosing active Hepatitis C Virus (HCV) infection. The goal is to accelerate diagnosis and linkage to care for individuals with active HCV infection, which is a critical step towards eliminating the global HCV epidemic by 2030 as targeted by the World Health...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $147,486 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Icahn School of Medicine at Mount Sinai in New York. The grant will support research to characterize the immune response and transcriptional programs underlying T cell exhaustion in a mouse model of chronic hepacivirus infection, which recapitulates key features of hepatitis C virus (HCV) infection in humans. The goal...
- This Project Grant award from the National Institutes of Health (NIH) Office of Research Infrastructure Programs (CFDA 93.351) aims to develop strategies to prevent or eliminate unwanted immune responses toward adeno-associated virus (AAV)-delivered anti-HIV broadly neutralizing antibodies (bNAbs). The $887,626 award to the University of Miami will fund a 2-year study that enrolls 10 rhesus monkeys to test the efficacy of immunomodulatory drugs, such as rapamycin and ibrutinib, in inducing...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), is providing $402,985 to the Research Institute at Nationwide Children's Hospital to develop a collaborative cross mouse model for studying chronic Salmonella Typhi infection. The goal is to create a more physiologically relevant animal model for studying chronic typhoid fever in humans, focusing on the role of...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is focused on understanding the underlying mechanisms that allow bats to host viruses that cause high mortality in humans, such as rabies, Hendra, Nipah, Ebola, and SARS. The $455,692 award will enable experimental evolution studies on vesicular stomatitis virus (VSV) in bat cell lines to test theoretical predictions about how...
ANIMAL MODEL TO STUDY HETEROGENEOUS OUTCOMES OF HCV INFECTION AND PATHOGENESIS - ABSTRACT APPROXIMATELY 30% OF HEPATITIS C VIRUS-INFECTED PERSONS SPONTANEOUSLY CLEAR THE VIRUS WITHIN SIX MONTHS. THE REMAINING 70% DEVELOP CHRONIC INFECTION. OF THOSE WITH CHRONIC HCV INFECTION, THE RISK OF CIRRHOSIS RANGES FROM 15% TO 30% WITHIN 20 YEARS. THE VIRAL AND IMMUNE CORRELATES OF THESE DIFFERENT OUTCOMES OF INFECTION AND PATHOGENESIS REMAIN POORLY STUDIED, MAINLY DUE TO THE LACK OF AN INFORMATIVE ANIMAL MODEL. WE DEVELOPED SURROGATE ANIMAL MODELS FOR HCV USING A RODENT HCV-LIKE VIRUS ISOLATED FROM FERAL BROWN RATS (RATTUS NORVEGICUS), RHV-RN1 (RN-1). SO FAR, STUDIES OF RN-1 INFECTION AND IMMUNITY IN LAB MICE HAVE REVEALED THAT NORMAL IMMUNOCOMPETENT MICE DO NOT DEVELOP PROLONGED OR CHRONIC HCV-LIKE INFECTIONS. NOTABLY, CHRONIC HCV AND RHV INFECTIONS CAN BE STUDIED IN THEIR NATURAL HOST, HUMANS AND RATS, RESPECTIVELY. HOWEVER, HOW HCV EVADES IMMUNITY DURING THE ACUTE PHASE, A PREREQUISITE FOR DEVELOPING CHRONIC INFECTION, REQUIRES ANIMAL MODELS THAT ALLOW COMPARATIVE ANALYSES OF HCV-LIKE CLEARANCE AND PERSISTENCE AND MECHANISTIC ANALYSIS OF INNATE AND ADAPTIVE IMMUNE RESPONSES. TO CREATE SUCH MODELS, WE ISOLATED SEVERAL NEW RHV VARIANTS FROM FERAL RATS AND USED THESE AS A POOL FOR SERIAL PASSAGING AND ADAPTATION IN MICE. AFTER SEVERAL PASSAGES, WE IDENTIFIED A MOUSE- ADAPTED VARIANT (RN-2M) THAT PRODUCED DELAYED CLEARANCE OR CHRONIC INFECTION IN NORMAL LAB MICE. SUBSEQUENTLY, WE IDENTIFIED THE PARENT RAT VIRUS RN-2, AND ITS INFECTION CLEARED WITHIN 3-4 WEEKS IN MICE. THE PROJECT SEEKS TO IDENTIFY THE VIRAL AND IMMUNE DETERMINANTS OF HETEROGENOUS OUTCOMES OF HCV INFECTION AND PATHOGENESIS. CONSIDERING THE STRENGTHS AND WEAKNESSES OF THE RAT AND MOUSE MODELS, WE PROPOSE A COMPARATIVE BIOLOGY APPROACH WHERE THE NEW RN-2M INFECTION IN THE MOUSE MODEL, DUE TO THE AVAILABILITY OF VAST RESOURCES, WILL BE USED TO DEVELOP AND TEST HYPOTHESES, AND THE RAT MODEL WILL BE USED FOR VALIDATION OF KEY FINDINGS. SPECIFIC AIM 1 IS TO IDENTIFY THE VIRAL CORRELATES OF SPONTANEOUS CLEARANCE AND CHRONIC INFECTION. OUR NEW DATA INDICATE THAT RN-2M CONSTANTLY EVOLVES AND MODULATES INNATE IMMUNE CELLS IN THE LIVER OF INFECTED MICE TO ESTABLISH A PROLONGED OR CHRONIC INFECTION. WE WILL COMPARE THE NATURE OF INFECTION, EVOLUTION, AND IMMUNOGENICITY OF CLONE- RESCUED RN-2 AND RN-2M TO IDENTIFY VIRAL CORRELATES OF ACUTE CLEARANCE, DELAYED CLEARANCE, AND CHRONIC INFECTION IN MICE AND SUBSEQUENTLY IN RATS. SPECIFIC AIM 2 IS TO IDENTIFY THE IMMUNE CORRELATES OF CHRONIC INFECTION AND LIVER DISEASES. WE WILL USE RHV-SPECIFIC MOUSE AND RAT MHC TETRAMERS AND E2 PROTEIN TETRAMERS, EX VIVO ANTIGEN STIMULATION, PASSIVE ANTIBODY, AND IN VIVO T AND B CELL TRANSFER, AND CELL DEPLETION EXPERIMENTS TO DEFINE THE ROLE OF T AND B CELLS IN DETERMINING DIFFERENT OUTCOMES OF RHV INFECTION AND PATHOGENESIS. WE EXPECT THAT THE SOLID RATIONALE BEHIND OUR APPROACH WILL YIELD A BIOLOGICALLY RELEVANT AND WIDELY ACCESSIBLE LAB MOUSE MODEL FOR HCV AND GAIN NOVEL AND MECHANISTIC INSIGHTS INTO HCV IMMUNE EVASION AND PATHOGENESIS. THIS KNOWLEDGE IS CRUCIAL FOR DEVELOPING NEW STRATEGIES TO PREVENT CHRONIC HCV INFECTIONS AND ASSOCIATED LIVER DISEASES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $781.0k | 6/2/25 | ||
| Not listed | $78.1k | 8/7/24 | ||
| Not listed | $78.1k | 8/7/24 | ||
| Not listed | $716.9k | 5/29/24 | ||
| Not listed | $716.9k | 5/29/24 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
GR002669SA1S | Emory University | Project Grant R01AI183877 | $27.3k | 4/22/25 | |
700349042501S | Emory University | Project Grant R01AI183877 | $245.7k | 11/26/24 | |
SUB318AM1GR002669SA1S | Emory University | Project Grant R01AI183877 | $273.0k | 11/26/24 |